Coeptis Therapeutics Inc
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio and rights are licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, natural killer cell therapy tec… Read more
Coeptis Therapeutics Inc (COEP) - Total Liabilities
Latest total liabilities as of September 2025: $3.26 Million USD
Based on the latest financial reports, Coeptis Therapeutics Inc (COEP) has total liabilities worth $3.26 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Coeptis Therapeutics Inc - Total Liabilities Trend (2004–2024)
This chart illustrates how Coeptis Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Coeptis Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Coeptis Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Chino Commercial Bancorp
PINK:CCBC
|
USA | $445.42 Million |
|
Paxman AB
PINK:PXMBF
|
USA | $59.89 Million |
|
Tata Steel (Thailand) Public Company Limited
BK:TSTH
|
Thailand | ฿2.46 Billion |
|
Thai Coconut Public Company Limited
BK:COCOCO
|
Thailand | ฿2.74 Billion |
|
VirTra Inc
NASDAQ:VTSI
|
USA | $19.37 Million |
|
Adicet Bio Inc
NASDAQ:ACET
|
USA | $33.15 Million |
|
PEDEVCO Corp
NYSE MKT:PED
|
USA | $20.52 Million |
|
Solytech Enterprise Corp
TW:1471
|
Taiwan | NT$122.33 Million |
Liability Composition Analysis (2004–2024)
This chart breaks down Coeptis Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.21 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.26 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Coeptis Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Coeptis Therapeutics Inc (2004–2024)
The table below shows the annual total liabilities of Coeptis Therapeutics Inc from 2004 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $5.04 Million | +45.61% |
| 2023-12-31 | $3.46 Million | +11.25% |
| 2022-12-31 | $3.11 Million | -29.50% |
| 2021-12-31 | $4.41 Million | -18.90% |
| 2020-12-31 | $5.44 Million | +3392.95% |
| 2019-12-31 | $155.85K | +151.08% |
| 2018-12-31 | $62.07K | -91.20% |
| 2005-12-31 | $705.22K | +126.80% |
| 2004-12-31 | $310.94K | -- |